Xeljanz demand trends
In 3Q17, Pfizer’s (PFE) Xeljanz reported revenue of ~$348 million, marking YoY (year-over-year) growth of ~48.1%. The drug saw sales of $935 million in the first nine months of 2017, a 44.1% YoY rise. In 3Q17, the drug’s new rheumatology prescriptions rose significantly. In September 2017, Xeljanz accounted for 9.8% of new prescriptions for RA (rheumatoid arthritis) in the United States, and ~10% in October 2017. By the end of 3Q17, the drug had been prescribed to almost 100,000 patients around the world. These numbers highlight Xeljanz’s potential to become the fastest growing therapy for advanced RA. Pfizer makes up ~1.3% of the Vanguard Value ETF (VTV).
The above diagram shows Xeljanz’s revenue growth in greater detail. Xeljanz is expected to enable Pfizer to compete with other RA players, such as AbbVie (ABBV), Johnson & Johnson (JNJ), and Amgen (AMGN).
Xeljanz label expansion
On December 14, 2017, the FDA approved Xeljanz 5-mg (milligram) and 11-mg formulations for patients with active psoriatic arthritis who have failed to respond adequately or have demonstrated intolerance to disease-modifying antirheumatic drugs and methotrexate.
On July 13, 2017, the FDA accepted a supplemental new drug application seeking regulatory approval for the use of oral Xeljanz to treat ulcerative colitis. The application must be reviewed by March 2018. In the next article, we’ll look at Pfizer’s Eucrisa.